Hanall Biopharma Reports KRW 40 Billion Q1 Sales, Up 11% Year-on-Year

Imeprobulvat D2T RA Clinical Trial Results
Announcement Moved Up to the Second Half of the Year

Hanall Biopharma announced on April 29 that its consolidated financial statements for the first quarter showed sales of KRW 40 billion, an 11% increase compared to the same period last year, according to a preliminary disclosure. Operating profit turned positive, reaching KRW 800 million.

Front view of HanAll Biopharma headquarters. HanAll Biopharma

Pharmaceutical business sales amounted to KRW 35.5 billion, up 12% year-on-year. The probiotic drug Biotop posted its highest-ever quarterly sales at KRW 7.6 billion, while the non-absorbable antibiotic Normix also grew by 10% to KRW 5.3 billion. In the hair loss treatment segment, the company expanded its lineup by launching the new product Minoxpil. The prostate cancer and central precocious puberty treatment 'Eligard' continued its growth in the precocious puberty sector thanks to increased prescriptions of the six-month formulation.

In the research and development sector, the next-generation FcRn inhibitor, Imeprobulvat, is progressing rapidly. Studies are underway for a total of six autoimmune diseases through its partner, Immunovant.

Notably, the registration clinical trial for difficult-to-treat rheumatoid arthritis (D2T RA) has accelerated patient enrollment, bringing forward the results announcement from the previously planned 2027 to the second half of this year. Additionally, the topline results for the clinical proof-of-concept (PoC) study for another indication, cutaneous lupus erythematosus (CLE), are also scheduled for release in the second half of this year.

A Hanall Biopharma representative stated, "The robust growth in pharmaceutical sales is strengthening our stable revenue base," and added, "Starting with major clinical results for Imeprobulvat in the second half of the year, we will systematically demonstrate our mid- to long-term growth potential."

In April, Hanall Biopharma released the results of a Phase 3 clinical trial for Batoclimab, the lead compound of Imeprobulvat, in thyroid eye disease (TED). Although Batoclimab did not meet its primary endpoint, results showed that in the subgroup of patients with concurrent hyperthyroidism, high-dose administration restored thyroid hormone levels to the normal range.

This content was produced with the assistance of AI translation services.